Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1081-1100 of 1,738 trials

Acute Myeloid Leukemia: Midostaurin and Gemtuzumab Ozogamicin

We are studying a new combination treatment for patients with acute myeloid leukemia to see if it is safe and effective alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology

Breast Cancer: Genomics Guided Therapy Study

We are exploring whether a personalized treatment approach after surgery can improve outcomes for patients with early high-risk breast cancer. This study will assess survival rates and the safety of the new therapy.

Early Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Retinoblastoma: New Treatment Strategies

We are studying the effectiveness of a new chemotherapy method and other conservative treatments for children with retinoblastoma. Our goal is to see how well these treatments control the disease and support visual health.

Retinoblastoma Treatment>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOphthalmology

Early Stage Arthritis: Baricitinib Study

We are studying the effects of baricitinib on joint inflammation in people with early stage arthritis. The trial will also look at safety and potential indicators of disease progression.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Standard MedicinesRheumatology

Colorectal Cancer: New Treatment with 5-Fluorouracil, Panitumumab, and Sotorasib

We are studying a combination of medications for patients with advanced colorectal cancer who cannot receive standard chemotherapy. The goal is to see if this treatment helps control the disease and improves quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Triple Negative Breast Cancer: Atezolizumab, Vinorelbine, and Cyclophosphamide Study

We are studying a combination of three drugs to see if it can activate the immune system in patients with advanced triple negative breast cancer who have been treated with prior immunotherapy. The goal is to evaluate how well this treatment works and its safety.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Cervical Cancer: Relatlimab and Nivolumab Study

We are exploring whether combining Relatlimab with Nivolumab is more effective than Nivolumab alone for treating locally advanced cervical cancer. This study aims to find better treatment options for patients.

Cervical Cancer>2 yearsEfficacy phase (II)Oncology

Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

Type 1 DiabetesEfficacy phase (II)16-20 visitsInvestigational MedicinesEndocrinologyInternal Medicine

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Colorectal Cancer: New Immunotherapy Treatment

We are studying a combination of Pembrolizumab and a Dendritic Cell Vaccine, followed by other medications, for patients with advanced colorectal cancer that hasn't responded to prior treatments. The goal is to see if this approach improves survival and safety.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Rotator Cuff Disease: Botulinum Toxin Treatment

We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.

Shoulder Tendonitis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesOrthopedics and Traumatology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesDermatologyOncology

Extra-Mammary Paget's Disease: PAGETEX Device Study

We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.

Paget's Disease of the Vulva6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Multiple Myeloma: Teclistamab with Daratumumab or Lenalidomide

We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Malignant Pleural Mesothelioma: Innovative Treatment Study

We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.

Malignant Pleural Mesothelioma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Mesothelioma: Talazoparib Maintenance Treatment

We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.

Advanced Malignant Mesothelioma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Ginisortamab for Advanced Pancreatic Cancer

We are studying the safety and effectiveness of ginisortamab combined with standard treatments for metastatic pancreatic cancer. This trial will help us understand how well it works and its potential side effects.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesGastroenterologyOncology

Non-Small Cell Lung Cancer: 68GaNOTA-Anti-MMR Imaging Study

We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngologyPulmonology